ALNYLAM PHARMACEUTICALS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 151.4 USD | -0.60% |
|
+0.71% | -20.92% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
Financials (USD)
| Sales 2024 * | 1.87B | Sales 2025 * | 2.26B | Capitalization | 19.26B |
|---|---|---|---|---|---|
| Net income 2024 * | -455M | Net income 2025 * | -256M | EV / Sales 2024 * | 9.61 x |
| Net cash position 2024 * | 1.26B | Net cash position 2025 * | 475M | EV / Sales 2025 * | 8.31 x |
| P/E ratio 2024 * |
-42.8
x | P/E ratio 2025 * |
-81.7
x | Employees | 2,100 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.59% |
More Fundamentals
* Assessed data
More news
Latest transcript on Alnylam Pharmaceuticals, Inc.
More recommendations
More press releases
More news
| 1 day | -0.60% | ||
| 1 week | +0.71% | ||
| Current month | +5.15% | ||
| 1 month | -2.91% | ||
| 3 months | -10.97% | ||
| 6 months | -7.99% | ||
| Current year | -20.92% |
1 week
149.52
155.49
1 month
141.98155.49
Current year
141.98199.38
1 year
141.98218.88
3 years
117.58242.97
5 years
65.81242.97
10 years
31.38242.97
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 61 | 16-09-18 | |
Jeffrey Poulton
DFI | Director of Finance/CFO | 56 | 19-08-12 |
Piyush Sharma
CMP | Compliance Officer | - | 22-09-20 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
David Pyott
BRD | Director/Board Member | 70 | 15-12-17 |
Charles Sigal
BRD | Director/Board Member | 72 | 22-08-21 |
Margaret Hamburg
BRD | Director/Board Member | 68 | 19-01-09 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 5.08% | 0 M€ | -2.17% | - | |
| 4.04% | 2 M€ | -.--% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-08 | 152.3 | -1.32% | 452,321 |
| 24-05-07 | 154.3 | +2.06% | 353,438 |
| 24-05-06 | 151.2 | -0.73% | 289,746 |
| 24-05-03 | 152.3 | +1.34% | 452,160 |
| 24-05-02 | 150.3 | +0.23% | 660,180 |
Delayed Quote Nasdaq, May 09, 2024 at 04:00 pm EDT
More quotes
Alnylam Pharmaceuticals, Inc. is a clinical-stage company. The Company is engaged in developing mRNA cell therapies for the treatment of autoimmune diseases. The Companyâs lead product candidate, Descartes-08, is an autologous mRNA CAR-T directed against the B cell maturation antigen (BCMA). Descartes-08 targets BCMA, which exists on the surface of long-lived plasma cells and plasmacytoid dendritic cells. Descartes-08 is in Phase IIb clinical development for patients with generalized myasthenia gravis (MG). Its other product candidate includes Descartes-15 and Descartes-33. Descartes-15 is a next-generation, autologous anti-BCMA mRNA CAR-T. Using its proprietary technology and manufacturing platform, it designed Descartes-15 to be more resistant than Descartes-08 to recycling of the CAR upon multiple antigen exposures. It is developing Descartes-33 to deliver a combination of therapeutic proteins that target key drivers in the pathogenesis of autoimmunity.
Calendar
2024-05-16
- Annual General Meeting
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
29
Last Close Price
152.3
USD
Average target price
220.4
USD
Spread / Average Target
+44.71%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -20.92% | 19.26B | |
| +23.37% | 46.71B | |
| +48.83% | 41.8B | |
| -0.94% | 41.52B | |
| -5.86% | 29.55B | |
| +11.29% | 25.78B | |
| +3.20% | 12.14B | |
| -2.67% | 12.08B | |
| +30.23% | 11.98B | |
| +20.99% | 11.58B |
- Stock Market
- Equities
- ALNY Stock